<DOC>
	<DOC>NCT01639625</DOC>
	<brief_summary>They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.</brief_summary>
	<brief_title>Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Stages IIA and IIB FIGO classification. Age between 21 to 70 years. ECOG performance status 01. No history of another neoplastic disease. Value of Hemoglobin ≥ 9 g / l. Total leukocyte count ≥ 3.0 x 109 / L. Absolute neutrophil count ≥ 1.5 x 109 / L. Platelets ≥ 100,000 x mm3. Total bilirubin ≤ 1.5 times ULN, SGOT and SGPT ≤ 2.5 times upper limit of normal. Creatinine ≤ 2 mg / dL and creatinine clearance calculated ≥ 60 ml / min(according to CockcroftGault formula) Patients of childbearing age who are using an adequate contraception method during treatment to prevent pregnancy. Life expectancy ≥ 12 months Measurable disease Informed consent signed by the patient Pregnancy and lactation period. Presence of lymph node metastases or hematogenous extrapelvic known. Uncontrolled intercurrent diseases, including active infection, symptomatic congestive heart failure, unstable angina or cardiac arrhythmia and psychiatric illness involving incompetence of the patient. Other malignancies, with the exception of basal cell carcinoma or other tumor that appropriate treatment is received showing a diseasefree period ≥ 5 years. Hepatitis B or C active, positive serology for HIV. Atopy history of severe / severe asthma. A history of autoimmune disease. Presence of significant abnormalities in ECG performed within 14 days prior to admission. Diseases that prevent the patient give informed consent or their ability to collaborate in the trial. Participating in another clinical trial "</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>